Algert Global LLC Acquires 11,720 Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Algert Global LLC raised its stake in Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) by 10.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,035 shares of the specialty pharmaceutical company’s stock after buying an additional 11,720 shares during the period. Algert Global LLC’s holdings in Juniper Pharmaceuticals were worth $606,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in JNP. Renaissance Technologies LLC boosted its position in Juniper Pharmaceuticals by 7.6% in the fourth quarter. Renaissance Technologies LLC now owns 254,300 shares of the specialty pharmaceutical company’s stock valued at $1,424,000 after buying an additional 17,900 shares during the period. Acadian Asset Management LLC boosted its position in Juniper Pharmaceuticals by 6.6% in the first quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,544 shares during the period. AWM Investment Company Inc. purchased a new position in Juniper Pharmaceuticals during the first quarter valued at approximately $475,000. Municipal Employees Retirement System of Michigan purchased a new position in Juniper Pharmaceuticals during the second quarter valued at approximately $1,192,000. Finally, Spark Investment Management LLC boosted its position in Juniper Pharmaceuticals by 33.0% in the second quarter. Spark Investment Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock valued at $303,000 after buying an additional 14,900 shares during the period. 36.75% of the stock is currently owned by hedge funds and other institutional investors.
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) opened at 4.675 on Friday. The firm’s 50-day moving average is $4.99 and its 200 day moving average is $4.74. The firm has a market cap of $50.70 million, a PE ratio of 6.040 and a beta of 0.28. Juniper Pharmaceuticals, Inc. has a 12-month low of $3.65 and a 12-month high of $7.15.
Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. The company had revenue of $13.96 million for the quarter, compared to analyst estimates of $11.84 million. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. Equities research analysts predict that Juniper Pharmaceuticals, Inc. will post ($0.51) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Algert Global LLC Acquires 11,720 Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/algert-global-llc-acquires-11720-shares-of-juniper-pharmaceuticals-inc-nasdaqjnp/1473081.html.
Several research analysts have commented on the stock. HC Wainwright reiterated a “hold” rating on shares of Juniper Pharmaceuticals in a report on Monday, May 15th. BMO Capital Markets upgraded shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $31.00 to $34.00 in a report on Friday, July 14th. ValuEngine cut shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Roth Capital set a $12.00 price target on shares of Juniper Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 6th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $17.58.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Want to see what other hedge funds are holding JNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juniper Pharmaceuticals, Inc. (NASDAQ:JNP).
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.